Strategy and Priorities

Our strategy is that of “Repositioning Rallis for Leadership”. We aim to achieve this by leveraging our legacy and strength and attaining our vision “to be among the top 3 leading enterprises by 2026” within farm inputs and chemistry-led businesses.

Key Focus Areas
  • Leveraging branding & manufacturing to drive volume growth in short term
  • Investing in R&D and manufacturing for long-term growth
  • Making Rallis attractive to partners for gaining access to new Active Ingredients
  • Building new contract manufacturing partnerships and sustaining existing ones

Key short, medium and long-term priorities of our business verticals are as follows:

Domestic Business:

New product introduction, strengthen and leverage brand power and distribution reach. Rebuild Institutional business.

International Business:

Maximise revenue from current Active Ingredient portfolio by scale-up / debottlenecking capacities.

Contract Manufacturing:

Sustain current contracts. Dedicated techno-commercial team for building new partnerships.

Seed Business:

Strengthen Kharif portfolio and undertake steps towards addressing the seasonality in the portfolio and hybrid seed production challenges.

Domestic Business:

Widening portfolio with value-added innovative formulations and build partnerships for niche Active Ingredients. Crop Nutrition focus to expand portfolio and market reach.

International Business:

Expand B2B partnership base and intensify B2C play in select products/geographies for revenue maximisation of existing portfolio. Resume few discontinued Active Ingredients Investment in Multi Purpose Plant (MPP).

Contract Manufacturing:

Build on initial success with new partners supported by appropriate investment in flexible manufacturing.

Seed Business:

Filling portfolio gaps in cotton, Rabi/spring maize with research focus. Build own portfolio in Mustard. Strengthen vegetable portfolio with own products and strategic partnership for inlicensed products.

Domestic Business:

Research-led new Active Ingredients and combination formulations to build a strong and innovative product portfolio.

International Business:

Widening portfolio with new Active Ingredients developing innovative formulation and investment in registration.

Contract Manufacturing:

Building long-term partnerships by showcasing manufacturing and research capabilities and investment commitments.

Seed Business:

Leveraging emerging technologies for value-added porfolio including Genetically Modified (GM) traits.